WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
OverviewZen RatingPriceValue
GrowthFinancialsMomentumSentimentForecastDividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the 9th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Price
Value
Graham Fair Value
Graham Fair Value %
P/E
Forward P/E
P/S
P/B
PEG
Free Cash Flow
Free Cash Flow Yield
Book Value
BVPS
EV
EV/EBITDA
BMY
BRISTOL MYERS SQUIBB CO
$66.82$34.2295.24%14.69x9.58x2.78x6.12x1.77x$11.44B8.38%$22.32B10.93$170.89B11.32
LLY
ELI LILLY & CO
$1,149.36$361.46217.98%38.52x31.22x12.87x31.94x1.68x$18.19B1.77%$33.88B37.96$1.13T31.60
SNY
SANOFI
$44.24N/AN/A23.67xN/A1.94x1.37xN/A$10.52B9.75%$78.64B32.25$127.47B8.90
AMGN
AMGEN INC
$437.23$167.75160.64%26.96x18.59x6.20x20.22x1.56x$10.18B4.31%$11.69B21.64$279.70B15.87
ABBV
ABBVIE INC
$256.46$99.19158.56%72.24x17.93x7.05x-75.76x0.98x$18.21B4.01%-$5.98B-3.38$517.45B26.94
MRK
MERCK & CO INC
$150.33$50.29198.95%118.37x54.20x5.58x8.84x1.07x$16.06B4.33%$41.93B16.98$417.95B29.01
GSK
GSK PLC
$49.89$16.52201.91%15.61xN/A2.26x4.25x19.36x$9.26B9.27%$23.53B11.74$120.13B9.74
PFE
PFIZER INC
$28.45$15.7580.62%37.43x9.47x2.55x1.90x0.74x$10.99B6.78%$85.19B14.95$224.37B20.86
GRFS
GRIFOLS SA
$7.80$9.09-14.20%11.37x8.15x0.61x0.87x0.43x$422.09M7.87%$6.13B8.91$15.62B8.44
GILD
GILEAD SCIENCES INC
$151.00N/AN/A-58.08x-335.10x6.16x15.83xN/A$12.94B6.90%$11.83B9.52$210.29B116.64
AZN
ASTRAZENECA PLC
$162.70$61.69163.74%24.14xN/A4.11x5.01x1.79x$10.68B4.23%$50.30B32.43$279.53B13.52
NVS
NOVARTIS AG
$159.99$49.25224.85%24.02xN/A5.38x7.32x3.04x$16.80B5.51%$41.54B21.81$345.49B12.19
JNJ
JOHNSON & JOHNSON
$275.23$91.88199.56%31.53x23.54x6.77x7.81x1.76x$22.24B3.36%$84.97B35.29$691.89B20.37
BIIB
BIOGEN INC
$220.83$118.1686.89%38.88x17.49x3.25x1.73x0.77x$2.68B8.20%$18.85B127.61$39.70B21.36
AMRN
AMARIN CORP PLC
$13.63N/AN/A-9.74x-190.90x1.52x0.65xN/A$15.57M5.49%$443.62M21.31$149.40M-6.59
SCLX
SCILEX HOLDING CO
$5.42N/AN/A-0.11x-5.96x1.18x-0.15xN/A-$17.80M-47.68%-$308.32M-44.74$151.41M-0.36
MDCX
MEDICUS PHARMA LTD
$0.17N/AN/A-0.07x-0.29xN/A-6.16xN/A-$29.32M-309.88%-$1.76M-0.03$7.31M-0.17
MIRA
MIRA PHARMACEUTICALS INC
$0.76N/AN/A-6.95x-4.16xN/A3.93xN/A-$4.64M-14.40%$8.16M0.19$28.50M-2.64
OGN
ORGANON & CO
$13.78$21.48-35.84%17.44x3.99x0.59x3.60x0.25x$567.00M15.67%$1.01B3.83$11.04B8.41
NSRX
NASUS PHARMA LTD
$3.74N/AN/A-3.43x-3.24xN/A3.98xN/A-$10.53M-25.46%$11.00M0.99$35.94MN/A
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Sep 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 14 points higher than the general drug manufacturer industry average of 36.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 43.11% over the past year, overperforming other general drug manufacturer stocks by 2 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $67.40, an upside of 0.87% from Bristol Myers Squibb Co's current stock price of $66.82.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Bristol Myers Squibb Co, 54.55% have issued a Strong Buy rating, 0% have issued a Buy, 45.45% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)


Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: C, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 66, which is 30 points higher than the general drug manufacturer industry average of 36.

LLY passed 26 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 54.71% over the past year, overperforming other general drug manufacturer stocks by 14 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,340.44, an upside of 16.62% from Eli Lilly & Co's current stock price of $1,149.36.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Eli Lilly & Co, 68.75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 6.25% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Sanofi (NASDAQ:SNY) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: B.

Sanofi (NASDAQ:SNY) has a Due Diligence Score of 31, which is -5 points lower than the general drug manufacturer industry average of 36. Although this number is below the industry average, our proven quant model rates SNY as a "B".

SNY passed 10 out of 38 due diligence checks and has average fundamentals. Sanofi has seen its stock lose -2.4% over the past year, underperforming other general drug manufacturer stocks by -44 percentage points.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 6.05%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.57%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 226.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.99%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.57%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 94.5% indicates that its dividend yield might not be sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 3.76%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.57%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 55.2% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.17% in the last day, and up 0.07% over the last week. Novartis Ag was the among the top losers in the drug manufacturers - general industry, dropping -1.9% yesterday.

Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 5 points higher than the general drug manufacturer industry average of 38. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 43.11% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 2 percentage points.

2. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 71, which is 33 points higher than the general drug manufacturer industry average of 38. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -21.21% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -62 percentage points.

3. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 48 points higher than the general drug manufacturer industry average of 38. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has gained 57.8% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 17 percentage points.

Are general drug manufacturer stocks a good buy now?

43.75% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 8.84% over the next year.

6.25% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 31.25% of general drug manufacturer stocks are rated B (Buy), 56.25% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 39.46x.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.